What is tirzepatide?
Tirzepatide is a GIP receptor and GLP-1 receptor agonist. ZEPBOUND prescribing information.
What is ZEPBOUND indicated for in the United States?
With a reduced-calorie diet and increased physical activity, the US ZEPBOUND label indicates long-term weight reduction for adults with obesity, or adults with overweight and at least one weight-related comorbid condition. ZEPBOUND prescribing information.
The label also indicates treatment of moderate to severe obstructive sleep apnea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity. ZEPBOUND prescribing information.
Tirzepatide side effects in ZEPBOUND trials
In two placebo-controlled ZEPBOUND trials in adults with obesity or overweight for weight reduction and long-term maintenance, nausea, diarrhea, vomiting, constipation and abdominal pain were among adverse reactions reported in at least 2% of ZEPBOUND-treated participants and more often than with placebo. ZEPBOUND prescribing information.
Who should not use ZEPBOUND?
ZEPBOUND is contraindicated with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2. ZEPBOUND prescribing information.
How is tirzepatide different from semaglutide?
Tirzepatide acts at GIP and GLP-1 receptors, while semaglutide is a GLP-1 receptor agonist. This is a mechanism comparison, not a head-to-head trial result or a guarantee of greater weight loss. The semaglutide guide and GLP-1 overview cover the separate reference labels. ZEPBOUND prescribing information, WEGOVY prescribing information.
